C2i Genomics
C2i Genomics is now part of Veracyte. We encourage you to follow Veracyte on LinkedIn.
C2i Genomics is now part of Veracyte. We encourage you to follow Veracyte on LinkedIn.
C2i Genomics is a company in the Health Care industry, founded in 2019 and headquartered in the United States. The company recently received a $100.00M Series B investment on April 15, 2021, with participation from notable investors including LionBird, Casdin Capital, iGlobe Partners, Driehaus Capital Management, Section 32, The Mark Foundation for Cancer Research, Duquesne Family Office, Alexandria Real Estate Equities, Gordon Asset Management, and NFX Bio. C2i Genomics' mission is to transform cancer care through the application of AI and genomics, which led to its acquisition by Veracyte. The merger with Veracyte opens up new opportunities and potential for growth in the evolving field of genomic diagnostics and personalized medicine.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $100.00M | 10 |
|
15 Apr 2021 |
| Series A | $12.00M | - | 09 Jun 2020 |
No recent news or press coverage available for C2i Genomics.
We care about your data, and we'd love to use cookies make your experience better.
